Verastem

Verastem CROIC

The Cash Return on Invested Capital (CROIC) of Verastem (VSTM) as of Nov 2, 2026 is -105.80 %. In the previous year, Cash Return on Invested Capital (CROIC) was -885.80 % — a change of -88.06% (higher).

CROIC

-105.80 %

YoY

-88.06%

Last updated:

Cash Return on Invested Capital (CROIC) of Verastem is 2025 -105.80 % . Cash Return on Invested Capital (CROIC) of Verastem was 2024 -885.80 % . It decreases by -88.06% higher compared to the previous year.

The Verastem CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-40.04 USD
Jan 1, 2019
-125.05 USD
Jan 1, 2020
-24.96 USD
Jan 1, 2021
-61.19 USD
Jan 1, 2022
-88.20 USD
Jan 1, 2023
-88.72 USD
Jan 1, 2024
-885.80 USD
Jan 1, 2025
-105.80 USD
The Verastem CROIC history
YEARCROICYoY
-105.80 %-88.06%
-885.80 %+898.42%
-88.72 %+0.59%
-88.20 %+44.15%
-61.19 %+145.15%
-24.96 %-80.04%
-125.05 %+212.30%
-40.04 %-50.65%
-81.14 %+98.71%
-40.84 %-8.58%
-44.67 %+0.81%
-44.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Verastem Stock analysis

What does Verastem do? Verastem Oncology develops and commercializes oncology drugs to improve cancer patient survival and quality of life. The company focuses on defactinib, an oral small molecule inhibitor of FAK and PYK2, and VS-6766, a RAF/MEK pathway inhibitor. Defactinib is being evaluated for combination therapy in solid tumors, while VS-6766 blocks MEK kinase activity and RAF phosphorylation. Verastem conducts clinical trials for cancers with limited treatment options including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer, and pancreatic cancer. The company markets and develops these products for healthcare providers and patients in the oncology segment. Verastem Oncology targets cancer patients requiring new treatment options, particularly in underserved areas like pancreatic cancer and mesothelioma. Its products are designed to address unmet medical needs in oncology through targeted therapies. Verastem generates revenue through the commercialization of defactinib and VS-6766 once approved. The company's business model relies on developing drugs for cancer treatment, with clinical trials focused on improving outcomes for patients with limited therapeutic options. Revenue streams come from product sales and potential partnerships for drug development and commercialization. Verastem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Verastem stock

Cash Return on Invested Capital (CROIC) of Verastem is -105.80 % in 2025.

Cash Return on Invested Capital (CROIC) of Verastem changed from -885.80 % to -105.80 %, representing a -88.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Verastem since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Verastem with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Verastem

All Key Metrics — Verastem